IRCT20171122037571N2 IRCT 2020-04-12 Tehran University of Medical Sciences Remdesivir in treatment of COVID-19 A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 2020-03-20 anticipated 120 Complete https://irct.ir/trial/46660 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: Medicine used in study was provided by International donation as Compassionate use under the supervision of the Ministry of Health and Medical Education. The study was approved by the TUMS ethics committee and received a Clinical Trial Authorization- CTA from the Food and Drug Administration before the study began. 2-3 COVID-19. Intervention group: In addition to standard treatment:(two-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days or alternatively, atazanavir OR three-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days and ribavirin 1200 mg BID for at least 5 days)Remdesivir is also prescribed for 5 days (for patients over 40 kg or more: Amp Remdesivir 200 mg IV infusion over 30 minutes once-daily dose, followed by 100 mg iv infusion over 30 minutes once-daily maintenance doses for next 4 days.For patients weighing less than 40 kg: Amp Remdesivir 5 mg/kg IV infusion over 30 minutes loading dose on day 1, followed by 2.5 mg/kg iv infusion over 30 minutes once-daily maintenance doses for next 4 days). No - There is not a plan to make this available Justification or reason for not sharing IPD is The DSMB decides how the results will be disseminated after reviewing the preliminary data.